Sanofi India (BOM:500674) Construction In Progress: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500674 Sanofi India Ltd BOM:500674
77 GF Score
Price ₹3,369.25
GF Value ₹4,402.68
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sanofi India Construction In Progress?

Sanofi India BOM:500674 -0.54% 77 Construction In Progress is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:500674 with a GF Score™ of 77/100 and a GF Value™ of ₹4,402.68 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Sanofi India's quarterly construction in progress increased from Sep. 2025 (₹0 Mil) to Dec. 2025 (₹143 Mil) but then declined from Dec. 2025 (₹143 Mil) to Mar. 2026 (₹0 Mil).

Sanofi India's annual construction in progress increased from Dec. 2023 (₹153 Mil) to Dec. 2024 (₹187 Mil) but then declined from Dec. 2024 (₹187 Mil) to Dec. 2025 (₹143 Mil).

Sanofi India Construction In Progress Historical Data

* Premium members only.

The historical data trend for Sanofi India's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi India Construction In Progress Chart

Sanofi India Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.00 229.00 153.00 187.00 143.00

Sanofi India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 163.00 0.00 143.00 0.00
BOM:500674
77GF Score
Sanofi India Ltd BOM:500674
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi India Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹0 Mil mean?
Sanofi India (BOM:500674) has a Construction In Progress of ₹0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Sanofi India and its competitors.
Is Sanofi India's Construction In Progress too high?
Sanofi India's current Construction In Progress is ₹0 Mil. Overall, Sanofi India has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi India's Construction In Progress compare to LLY and JNJ?
Sanofi India's Construction In Progress of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Sanofi India and its competitors. Sanofi India's current Construction In Progress is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi India stock overvalued right now?
Based on GuruFocus' analysis, Sanofi India (BOM:500674) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹4,402.68, compared to a current price of ₹3,369.25 — trading 23.5% below its estimated fair value. The current Construction In Progress is ₹0 Mil. Sanofi India's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Sanofi India (BOM:500674), the current Construction In Progress is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi India (BOM:500674) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued. The current stock price of ₹3,369.25 is trading 23.5% below its estimated GF Value™ of ₹4,402.68. GuruFocus considers Sanofi India to be Modestly Undervalued.

Key valuation signals for BOM:500674:

  • Construction In Progress: ₹0 Mil
  • GF Value™: ₹4,402.68 vs. price of ₹3,369.25 (23.5% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi India Business Description

Other Exchanges SANOFI:India
Address Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score

Get the complete analysis for BOM:500674

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,369.25
Price
₹4,402.68
GF Value